Evelo Biosciences

Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.

BiotechCambridge, MassachusettsFounded 2014Updated Apr 2, 2026

About Evelo Biosciences

Evelo Biosciences is a clinical-stage biotechnology company focused on developing oral therapies that work through the gut-body network. The company's approach involves using specific bacterial strains to modulate immune and metabolic pathways for treating inflammatory, metabolic, and oncologic diseases. Evelo's lead programs target conditions including inflammatory bowel disease, atopic dermatitis, and cancer, leveraging the connection between gut microbiome and systemic health.

Investors & Backers

Evelo Biosciences has received investment from 1 venture capital firm.

Flagship Pioneering

Cambridge, MAPre-Seed, Seed, Series A, Series B+

Full portfolios: Flagship Pioneering portfolio

Frequently Asked Questions

What does Evelo Biosciences do?

Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.

Who invested in Evelo Biosciences?

Evelo Biosciences has received investment from Flagship Pioneering. These venture capital firms and investors provide both capital and strategic support.

How much funding has Evelo Biosciences raised?

Evelo Biosciences has raised $260M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.

When was Evelo Biosciences founded?

Evelo Biosciences was founded in 2014 and is headquartered in Cambridge, Massachusetts.

What sector is Evelo Biosciences in?

Evelo Biosciences operates in the Biotech sector. Clinical-stage biotechnology company developing oral therapies that modulate the gut microbiome to treat inflammatory diseases.